报价延迟最少15分钟:2026/03/09 15:04 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
140.77 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-6.42/0.74
|
|
企业价值
30.73B
|
| 资产负债 |
|
每股账面净值
3.43
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
606.42M
|
|
每股收益
1.30
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from theUnited States from the sale of its commercial products. |
